EQS-News: Atriva Therapeutics GmbH / Key word(s): Letter of Intent Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology 18.09.2023 / 15:05 CET/CEST The issuer is solely responsible for the content of this announcement. Atriva Therapeut.
DGAP-News: Atriva Therapeutics GmbH / Key word(s): Conference Atriva Therapeutics to take part in upcoming scientific and industry conferences in early 2022 20.12.2021 / 10:00 The
DGAP-News: Atriva Therapeutics GmbH: Atriva Therapeutics to Speed up Development of COVID-19 Drug with Federal Funding
Atriva Therapeutics to Speed up Development of COVID-19 Drug with Federal Funding
21.04.2021 / 16:03
Atriva Therapeutics to Speed up Development of COVID-19 Drug with Federal Funding
German Federal Ministry of Education and Research (BMBF) awards Atriva up to €11.4 million for the clinical development of a drug to treat COVID-19
Product candidate ATR-002 could help hospital patients with COVID-19 avoid ventilation and intensive care treatment
Targeting RNA viruses and acting in the host cell, drug candidate can retain full activity even with SARS-CoV-2 variants
Therapeutic aims to inhibit replication of virus and to prevent overshooting immune response